The successful Phase III data de-risks the sNDA pathway for rezafungin’s expanded use and could drive revaluation of CorMedix’s commercial potential. Traders should monitor the pre-NDA discussion with the FDA and upcoming detailed data disclosures, which may further validate the benefit-risk profile ahead of regulatory submission.
CRMD drugs
CRMD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $7.82entry
- T+1 · 7mo ago −3.20%α −2.71% · $7.57
- T+5 · 7mo ago +1.02%α +0.62% · $7.90
- T+20 · 6mo ago +5.75%α +0.80% · $8.27
- T+60 · 4mo ago +1.53%α −3.24% · $7.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CorMedix announced positive Phase III topline results from the ReSPECT trial, showing that rezafungin met the primary endpoint of non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 for patients undergoing allogeneic HSCT. The drug demonstrated a favorable safety profile, particularly in reduced toxicity-related discontinuations and drug-drug interactions, supporting a potential sNDA submission in 2H26 for expanded prophylactic use.
Key Facts
- ReSPECT Phase III trial met primary FDA/EMA endpoint: non-inferiority in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for standard regimen).
- Rezafungin showed favorable secondary outcomes in safety, including lower rates of treatment discontinuation due to adverse events and fewer drug-drug interactions.
- sNDA submission to FDA expected in 2H26, following a pre-NDA meeting.
- Rezafungin is already approved for candidemia and invasive candidiasis; this data supports expansion into prophylaxis, a potential $2B+ US market.
- Mundipharma sponsored the trial and holds commercial rights outside the U.S.; Melinta (CorMedix subsidiary) handles U.S. distribution.
Financial Impact
Potential $2+ billion U.S. market opportunity for prophylactic use, based on company estimates.
Risk Factors
- Forward-looking market size estimates are speculative and subject to regulatory approval, adoption, and competition.
- Topline data may be revised as full dataset is analyzed.
- Commercial success depends on payer reimbursement and physician uptake despite current approval for treatment indications.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281520 |
Track record
21 reports on CRMD
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers